Relmada Therapeutics Q3 net loss narrows

Relmada Therapeutics

13/11/2025 21:15

Overview

Relmada Q3 net loss narrows to $10.1 mln from $21.7 mln in Q3 2024

Company completed $100 mln offering to support operations into 2028

Result Drivers

FINANCIAL SUPPORT - Completed $100 mln offering to support planned operations into 2028

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Net Income
-$10.10 mln


Analyst Coverage

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy."

Wall Street's median 12-month price target for Relmada Therapeutics Inc is $1.00, about 291% below its November 12 closing price of $3.91

Press Release: ID:nGNX1dRhS7

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)